Figure 3
From: Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model
Rapamycin aggravates illness of both mild and severe disease regardless of timing of treatment. Aggravated disease with more bodyweight loss and higher mortality upon daily 3 mg/kg bodyweight Rapamycin treatment compared to that of untreated control BALB/c mice suffering from infection with either (a) 2.5 × 103 PFU or (b) 1.25 × 104 PFU PR8 influenza virus. Naïve mice of comparable age were infected with stated inoculum size of PR8 virus. Rapamycin treatment was started from the stated days post-infection and control untreated mice received equal volume placebo solvent as daily intraperitoneal injection. Data are representative of at least three similar experiments and presented as mean ± s.d. (***p < 0.0001; n = 6/group).
